It is well understood that AD rapidly affects the brain through the aggregation of aberrant β-amyloid (Aβ) peptides and tau proteins (Murphy and LeVine, 2010; Lopes et al., 2016; Butterfield and Boyd-Kimball, 2018), and properly balanced proteostasis pathways are essential to hinder the activity of these aggregates. Here, MAPT is linked to Alzheimer disease.